Skip to main content
PBF logo

PBF — Investor Relations & Filings

Ticker · 1760 ISIN · TW0001760007 LEI · 54930078VUU2LBPR2729 TW Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1760

About PBF

http://www.pbf.com.tw

Panion & BF Biotech Inc. is a biotechnology company focused on pharmaceutical research, development, and manufacturing. Founded in 1976, the firm operates across several core sectors, including new drug innovation, medical aesthetics, and nutritional supplements. It is recognized for its "Total Aging Management" strategy, which addresses the health needs of an aging population through a diverse product portfolio. Key offerings include treatments for chronic kidney disease, specifically phosphate binders, as well as dermatological drugs, hair care solutions, and rapid diagnostic technologies. The company integrates clinical-grade pharmaceutical standards into its consumer health and aesthetic products, serving markets in chronic disease care and preventative wellness.

Recent filings

Filing Released Lang Actions
112年第3季財務報告書 — 202303_1760_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a consolidated financial report and auditor's review report for the third quarter of years 112 and 111 (Taiwanese calendar years). It includes detailed consolidated financial statements such as the balance sheet, income statement, statement of changes in equity, and cash flow statement, along with extensive notes on accounting policies and other disclosures. The presence of an auditor's review report (核閱報告) indicates this is a reviewed interim financial report rather than a full annual report. The document covers a period shorter than a full fiscal year (quarterly data) and contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-11-14 Chinese
112年第3季財務報告書 — 202302_1760_AI1.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report" for the second quarter of years 112 and 111 (Taiwanese calendar years). It contains detailed consolidated financial statements including balance sheets, income statements, cash flow statements, and notes to the financial statements. The document also includes an accountant's review report (核閱報告) which is a type of limited assurance engagement, not a full audit. The presence of detailed financial data, notes, and the accountant's review indicates this is a comprehensive interim financial report for a period shorter than a full fiscal year (quarterly or semi-annual). The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. The reference to "國際會計準則第三十四號「期中財務報導」" (IAS 34 Interim Financial Reporting) confirms this is an interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-11-14 Chinese
112年第3季財務報告書 — 202301_1760_AI1.pdf
Regulatory Filings
2023-11-14 Chinese
112年第3季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a tabular disclosure of investment holdings and related financial figures for a company named 寶齡富錦 (Bowlin Biotech Corp.) for the third quarter of the 112th year (likely referring to a fiscal period). It includes details such as shareholding percentages, original investment amounts, investment balances, and recognized investment gains or losses. The document is relatively short (1246 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report or earnings release. There is no indication that this is a full annual or interim report, audit report, or earnings release. It also does not fit categories like management changes, voting results, or capital changes. Given the nature of the data and the context, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2023-11-14 Chinese
112年第3季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of the company's investments in mainland China, including capital amounts, investment methods, cumulative investment amounts, and recognized investment gains or losses. It includes notes explaining the investment methods, accounting bases for investment gains/losses, and regulatory limits on investments. The document is relatively short (1933 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report or earnings release. It does not contain comprehensive financial statements or management discussion. The nature of the content aligns with a regulatory filing providing specific investment information as required by authorities, rather than a full annual or interim report or other categories like earnings release or management reports. Therefore, the best classification is Regulatory Filings (RNS).
2023-11-14 Chinese
112年第3季權益變動表
Interim / Quarterly Report Classification · 95% confidence The document contains detailed financial tables showing changes in equity for a company over the first three quarters of the year 2023 (民國112年前3季) and the same period in the previous year (民國111年前3季). The tables include line items such as common stock, capital surplus, legal reserve, special reserve, undistributed earnings, retained earnings, foreign currency translation adjustments, treasury stock, and total equity attributable to the parent company and non-controlling interests. This level of detailed financial data and the focus on equity changes over a partial fiscal year period indicate that this is a substantive financial report for an interim period rather than a brief announcement or a certification. The document length is 3607 characters, which is relatively short but contains actual financial data, not just a notice or announcement. Given the content and period covered (first three quarters), this fits the definition of an Interim / Quarterly Report (IR).
2023-11-14 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.